RXMD's only chance on NASDAQ is to make sure that long term shareholders are not screwed out of their hard earned investment. I cannot say what will happen, but I have to believe that the shares owned by insiders will have increased value, including the shares that were gifted in 2018 to employees, and the shares that were recently issued to directors. IMO